Pregnancy and opioids: new study aims to predict risks for mom and baby

NCT ID NCT03923374

Recruiting now Knowledge-focused Sponsor: Senthil Sadhasivam Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 600 pregnant women who are taking buprenorphine for opioid use disorder. Researchers will collect genetic samples, perform MRIs, and track health outcomes to better understand why some mothers and babies have complications. The goal is to improve treatment and reduce the severity of neonatal abstinence syndrome.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: buprenorphine
What this could lead to: If successful, this research could help doctors identify which mothers and babies are at higher risk for poor outcomes, leading to better, personalized care during pregnancy.
What could go wrong: This is an observational study, not a treatment trial, so it won't directly test a new therapy. Results may take years to translate into clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BUPRENORPHINE DEPENDENCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

opiate dependence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BUPRENORPHINE DEPENDENCE OPIOID USE, UNSPECIFIED OPIOID-USE DISORDER

Contacts and locations

Locations

UPMC Children's Hospital
RECRUITING

Pittsburgh, Pennsylvania, 15224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.